1. Analgesic Effects of Different Doses of Pregabalin in Chronic Low Back Pain: an Observational Study.
- Author
-
Roy, Sankar, Pandit, Paramita, Biswas, Arunava, and Bhattacharya, Dipasri
- Subjects
CHRONIC pain ,VISUAL analog scale ,PATIENTS' attitudes ,BEDTIME ,JUDGMENT (Psychology) - Abstract
Background: Chronic Low Back Pain (CLBP) is very common and is associated with significant patient burden, and health resource expenditure. A large proportion of CLBP patients are treated with routine analgesic medications with unsatisfactory results leading to frequent exploration of second line options including pregabalin. Therefore this study was conducted to assess the efficacy of pregabalin in decreasing CLBF and compare its different doses using visual analogue scale (VAS). Materials & Methods: A 24 weeks, prospective, non-interventional, observational study was performed on patients of either sex, aged 18 years to 60 years, belonging to ASA I, II and III categories. Patients were divided into 3 groups A, B and C according to different doses of pregabalin i.e. 75mg once per day, 75mg twice per day and 50mg twice per day respectively. Effectiveness was measured from the patient's perspective using reduction of Visual Analogue Scale (VAS) score. All the patients who enrolled in different study groups also received the following concomitant medications; Tablet Paracetamol 500 mg twice daily, Tablet Amitriptyline 10 mg once daily at bed time, Tablet Methylcobalamin 1500 mcg once daily, Capsule (Pantoprazole 40mg + Domperidone 30 mg) once daily. Choice of therapy was determined solely by the clinical judgment of the treating physician. Results: The study reflected greater reduction in VAS score of less than 5 (p <0.05) in Group B followed by Group C and A at 8
th week and a score of less than 3 (p < 0.05) at 24th week of follow up. Conclusion: When used in conjunction with standard therapy, pregabalin can relieve chronic low back pain. Pregabalin dosages of 75 mg twice daily followed by 50 mg twice daily, and 75 mg once daily are the most effective. These findings support pregabalin's therapeutic effectiveness and validate its applicability in the management of patients with this difficult ailment. [ABSTRACT FROM AUTHOR]- Published
- 2024